Idioma:

Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study

Moreau, Philippe ; Ghori, Razi ; Farooqui, Mohammed ; Marinello, Patricia ; San Miguel, Jesus

British journal of haematology, 2021-07, Vol.194 (1), p.e48-e51 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study
Autor: Moreau, Philippe ; Ghori, Razi ; Farooqui, Mohammed ; Marinello, Patricia ; San Miguel, Jesus
Assuntos: Acute Kidney Injury - chemically induced ; Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemical and Drug Induced Liver Injury - etiology ; Correspondence ; Dexamethasone ; Dexamethasone - administration & dosage ; Dexamethasone - adverse effects ; Female ; Hematology ; Humans ; Hypopituitarism - chemically induced ; immunotherapy ; Male ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Organ Failure - etiology ; Oligopeptides - administration & dosage ; Oligopeptides - adverse effects ; oncology ; Online Only ; Pembrolizumab ; Recurrence ; Salvage Therapy ; Treatment Outcome ; Young Adult
É parte de: British journal of haematology, 2021-07, Vol.194 (1), p.e48-e51
Notas: NCT02036502
ClinicalTrials.gov
SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ObjectType-Feature-3
ClinicalTrials.gov, NCT02036502
Editor: England: Blackwell Publishing Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 7 Avançar Ir para próxima página